Posted by Defense World Staff on Aug 4th, 2024
Price T Rowe Associates Inc. MD increased its position in DaVita Inc. (NYSE:DVA – Free Report) by 0.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,286 shares of the company’s stock after purchasing an additional 533 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.10% of DaVita worth $11,775,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also made changes to their positions in DVA. Newbridge Financial Services Group Inc. purchased a new position in shares of DaVita in the fourth quarter valued at $30,000. Principal Securities Inc. purchased a new position in shares of DaVita in the fourth quarter valued at $37,000. GAMMA Investing LLC purchased a new position in shares of DaVita in the fourth quarter valued at $60,000. Quest Partners LLC purchased a new position in shares of DaVita in the fourth quarter valued at $74,000. Finally, Quent Capital LLC boosted its stake in shares of DaVita by 21.0% in the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after purchasing an additional 101 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
DaVita Stock Up 1.5 %
Shares of NYSE:DVA opened at $139.52 on Friday. The stock has a market capitalization of $12.24 billion, a price-to-earnings ratio of 15.85, a price-to-earnings-growth ratio of 1.05 and a beta of 0.87. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $147.93. The company’s fifty day moving average is $140.72 and its two-hundred day moving average is $132.39. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43.
DaVita (NYSE:DVA – Get Free Report) last issued its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. The company had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 earnings per share. Equities analysts anticipate that DaVita Inc. will post 9.62 EPS for the current year.
Insiders Place Their Bets
In other DaVita news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the sale, the director now directly owns 10,954 shares of the company’s stock, valued at $1,520,524.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on DVA shares. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Truist Financial increased their price objective on shares of DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, May 15th. TD Cowen increased their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Barclays increased their price objective on shares of DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research note on Monday, May 6th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $146.00.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Stories
- Five stocks we like better than DaVita
- Consumer Staples Stocks, Explained
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- How to Start Investing in Real Estate
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Pros And Cons Of Monthly Dividend Stocks
- MarketBeat Week in Review – 7/29 – 8/2
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
Public Employees Retirement Association of Colorado Has $337,000 Stock Position in C3.ai, Inc.
Public Employees Retirement Association of Colorado Trims Stock Holdings in OSI Systems, Inc.
Federal Agricultural Mortgage Co. Shares Sold by Public Employees Retirement Association of Colorado
Public Employees Retirement Association of Colorado Lowers Holdings in Carter’s, Inc.
Public Employees Retirement Association of Colorado Trims Holdings in Envista Holdings Co.
Public Employees Retirement Association of Colorado Sells 1,214 Shares of NorthWestern Energy Group, Inc.
